All In Biotech

Drug Trial Radar · NCT07141381

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

A Phase 1, Open-label, 3-Period, Randomized 2-Sequence Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Aug 27, 2025

Primary completion

Dec 17, 2025

Study completion Apr 16, 2026

Sponsor

Lead sponsor
Voronoi, IncIndustry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants. The primary aim of this study is to assess the impact of food and rabeprazole co-administration on the systemic exposure of VRN110755. Safety and tolerability will also be evaluated.

Conditions

  • Healthy

Interventions

  • VRN110755Drug

    VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.

  • RabeprazoleDrug

    Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC₀-inf) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
  2. Maximum Observed Plasma Concentration (Cmax) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
  3. Time to Maximum Observed Concentration (Tmax) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
  4. Comparison of Pharmacokinetic Parameters (AUC and Cmax Ratios) Across Treatment ConditionsTime frame: Up to 312 hours post-dose (for each treatment period)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.